Spectrum reaches patent settlement with Fresenius

14-07-2016

US biopharmaceutical company Spectrum Pharmaceuticals announced yesterday that it had reached a settlement with UK healthcare company Fresenius Kabi in a patent dispute centring on the drug Folotyn (pralatrexate).


Spectrum, Fresenius, Folotyn, pralatrexate, patent

LSIPR